Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia

Src/Abl inhibitors are compatible with imatinib

Thomas O'Hare, Denise K. Walters, Eric P. Stoffregen, Daniel W. Sherbenou, Michael Heinrich, Michael W N Deininger, Brian Druker

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Purpose: Chronic myeloid leukemia (CML) is effectively treated with imatinib. However, reactivation of Bcr-Abl via kinase domain mutations that reduce sensitivity to imatinib can cause relapse. As combination therapy is frequently used to prevent emergence of resistance, the combination of imatinib with an inhibitor of imatinib-resistant Bcr-Abl mutants (e.g., Src/Abl inhibitors AP23848 and BMS-354825) was investigated. Experimental Design: To test this approach, cellular proliferation and Bcr-Abl tyrosine phosphorylation assays were done on Ba/F3 cells expressing wild-type (WT) Bcr-Abl and four common imatinib-resistant mutants (Y253F, E255K, T315I, and M351T). Colony-forming assays with primary CML cells were also done. Results: Both Src/Abl inhibitors retained full inhibitory capacity when coadministered with imatinib at concentrations above typical clinical levels. For cells expressing WT Bcr-Abl or the marginally imatinib-resistant mutant M351T, inclusion of imatinib at therapeutic levels enhanced the effects of the Src/Abl inhibitors. By comparison, for the highly imatinib-resistant mutants Y253F and E255K, inclusion of imatinib at clinical levels resulted in only a slight enhancement beyond the effects of the Src/Abl inhibitors. None of the inhibitors affected Bcr-AblT315I cells. Colony-forming assays with primary CML cells yielded analogous results. Conclusions: Our results indicate that Src/Abl inhibitors are compatible with imatinib and suggest that combined Abl inhibitor therapy is a feasible treatment strategy for patients with CML.

Original languageEnglish (US)
Pages (from-to)6987-6993
Number of pages7
JournalClinical Cancer Research
Volume11
Issue number19 I
DOIs
StatePublished - Oct 1 2005

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Drug Resistance
Therapeutics
Myeloid Cells
Imatinib Mesylate
Tyrosine
Research Design
Phosphotransferases
Phosphorylation
Cell Proliferation
Recurrence
Mutation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia : Src/Abl inhibitors are compatible with imatinib. / O'Hare, Thomas; Walters, Denise K.; Stoffregen, Eric P.; Sherbenou, Daniel W.; Heinrich, Michael; Deininger, Michael W N; Druker, Brian.

In: Clinical Cancer Research, Vol. 11, No. 19 I, 01.10.2005, p. 6987-6993.

Research output: Contribution to journalArticle

O'Hare, Thomas ; Walters, Denise K. ; Stoffregen, Eric P. ; Sherbenou, Daniel W. ; Heinrich, Michael ; Deininger, Michael W N ; Druker, Brian. / Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia : Src/Abl inhibitors are compatible with imatinib. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 19 I. pp. 6987-6993.
@article{120ad22935f64853845a918975d03b22,
title = "Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib",
abstract = "Purpose: Chronic myeloid leukemia (CML) is effectively treated with imatinib. However, reactivation of Bcr-Abl via kinase domain mutations that reduce sensitivity to imatinib can cause relapse. As combination therapy is frequently used to prevent emergence of resistance, the combination of imatinib with an inhibitor of imatinib-resistant Bcr-Abl mutants (e.g., Src/Abl inhibitors AP23848 and BMS-354825) was investigated. Experimental Design: To test this approach, cellular proliferation and Bcr-Abl tyrosine phosphorylation assays were done on Ba/F3 cells expressing wild-type (WT) Bcr-Abl and four common imatinib-resistant mutants (Y253F, E255K, T315I, and M351T). Colony-forming assays with primary CML cells were also done. Results: Both Src/Abl inhibitors retained full inhibitory capacity when coadministered with imatinib at concentrations above typical clinical levels. For cells expressing WT Bcr-Abl or the marginally imatinib-resistant mutant M351T, inclusion of imatinib at therapeutic levels enhanced the effects of the Src/Abl inhibitors. By comparison, for the highly imatinib-resistant mutants Y253F and E255K, inclusion of imatinib at clinical levels resulted in only a slight enhancement beyond the effects of the Src/Abl inhibitors. None of the inhibitors affected Bcr-AblT315I cells. Colony-forming assays with primary CML cells yielded analogous results. Conclusions: Our results indicate that Src/Abl inhibitors are compatible with imatinib and suggest that combined Abl inhibitor therapy is a feasible treatment strategy for patients with CML.",
author = "Thomas O'Hare and Walters, {Denise K.} and Stoffregen, {Eric P.} and Sherbenou, {Daniel W.} and Michael Heinrich and Deininger, {Michael W N} and Brian Druker",
year = "2005",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-05-0622",
language = "English (US)",
volume = "11",
pages = "6987--6993",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19 I",

}

TY - JOUR

T1 - Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia

T2 - Src/Abl inhibitors are compatible with imatinib

AU - O'Hare, Thomas

AU - Walters, Denise K.

AU - Stoffregen, Eric P.

AU - Sherbenou, Daniel W.

AU - Heinrich, Michael

AU - Deininger, Michael W N

AU - Druker, Brian

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Purpose: Chronic myeloid leukemia (CML) is effectively treated with imatinib. However, reactivation of Bcr-Abl via kinase domain mutations that reduce sensitivity to imatinib can cause relapse. As combination therapy is frequently used to prevent emergence of resistance, the combination of imatinib with an inhibitor of imatinib-resistant Bcr-Abl mutants (e.g., Src/Abl inhibitors AP23848 and BMS-354825) was investigated. Experimental Design: To test this approach, cellular proliferation and Bcr-Abl tyrosine phosphorylation assays were done on Ba/F3 cells expressing wild-type (WT) Bcr-Abl and four common imatinib-resistant mutants (Y253F, E255K, T315I, and M351T). Colony-forming assays with primary CML cells were also done. Results: Both Src/Abl inhibitors retained full inhibitory capacity when coadministered with imatinib at concentrations above typical clinical levels. For cells expressing WT Bcr-Abl or the marginally imatinib-resistant mutant M351T, inclusion of imatinib at therapeutic levels enhanced the effects of the Src/Abl inhibitors. By comparison, for the highly imatinib-resistant mutants Y253F and E255K, inclusion of imatinib at clinical levels resulted in only a slight enhancement beyond the effects of the Src/Abl inhibitors. None of the inhibitors affected Bcr-AblT315I cells. Colony-forming assays with primary CML cells yielded analogous results. Conclusions: Our results indicate that Src/Abl inhibitors are compatible with imatinib and suggest that combined Abl inhibitor therapy is a feasible treatment strategy for patients with CML.

AB - Purpose: Chronic myeloid leukemia (CML) is effectively treated with imatinib. However, reactivation of Bcr-Abl via kinase domain mutations that reduce sensitivity to imatinib can cause relapse. As combination therapy is frequently used to prevent emergence of resistance, the combination of imatinib with an inhibitor of imatinib-resistant Bcr-Abl mutants (e.g., Src/Abl inhibitors AP23848 and BMS-354825) was investigated. Experimental Design: To test this approach, cellular proliferation and Bcr-Abl tyrosine phosphorylation assays were done on Ba/F3 cells expressing wild-type (WT) Bcr-Abl and four common imatinib-resistant mutants (Y253F, E255K, T315I, and M351T). Colony-forming assays with primary CML cells were also done. Results: Both Src/Abl inhibitors retained full inhibitory capacity when coadministered with imatinib at concentrations above typical clinical levels. For cells expressing WT Bcr-Abl or the marginally imatinib-resistant mutant M351T, inclusion of imatinib at therapeutic levels enhanced the effects of the Src/Abl inhibitors. By comparison, for the highly imatinib-resistant mutants Y253F and E255K, inclusion of imatinib at clinical levels resulted in only a slight enhancement beyond the effects of the Src/Abl inhibitors. None of the inhibitors affected Bcr-AblT315I cells. Colony-forming assays with primary CML cells yielded analogous results. Conclusions: Our results indicate that Src/Abl inhibitors are compatible with imatinib and suggest that combined Abl inhibitor therapy is a feasible treatment strategy for patients with CML.

UR - http://www.scopus.com/inward/record.url?scp=26444442452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444442452&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-0622

DO - 10.1158/1078-0432.CCR-05-0622

M3 - Article

VL - 11

SP - 6987

EP - 6993

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19 I

ER -